Decreased levels of CD44 protein and mRNA in prostate carcinoma: Correlation with tumor grade and ploidy

Cancer

Volumn 78, Issue 7, 1996, Pages 1461-1469

  Kallakury, Bhaskar V S ^a   Yang, Fan ^a   Figge, James ^a   Smith, Karen E ^a   Kausik, Sankar J ^a   Tacy, Nelson J ^a   Fisher, Hugh A G ^a   Kaufman, Ronald ^a   Figge, Helen ^a   Ross, Jeffrey S ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

adenocarcinoma; CD44s; CD44v; mRNA; polymerase chain reaction; prostate; reverse transcriptase

Indexed keywords

HERMES ANTIGEN; MESSENGER RNA;

ANEUPLOIDY; ANTIGEN EXPRESSION; ARTICLE; CANCER GRADING; DNA CONTENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECRETORY CELL;

ADENOCARCINOMA; ANTIGENS, CD44; DNA, NEOPLASM; DOWN-REGULATION; HUMANS; MALE; PLOIDIES; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; RNA, MESSENGER; RNA, NEOPLASM; RNA-DIRECTED DNA POLYMERASE;

EID: 0346422159     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19961001)78:7<1461::AID-CNCR13>3.0.CO;2-Y     Document Type: Article

References (53)

1. Haynes BF, Liao HX, Patton KL. The transmembrane hyaluronate receptor (CD44): multiple functions, multiple forms. Cancer Cells 1991;3:347-50.
2. Underhill C. CD44: the hyaluronan receptor. J Cell Sci 1992;103:293-8.
3. Lesley J, Hyman R, Kincade PW. CD44 and its interaction with the extracellular matrix. Adv Immunol 1993;54:271-335.
4. Brown T, Bouchard T, St. John T, Wagner E, Carter WG. Human keratinocytes express a new CD44 core protein (CD44 E) as a heparin-sulfate intrinsic membrane proteoglycan with additional exons. J Cell Biol 1991;113:207-21.
5. Cooper DL, Dougherty G, Harn HJ, Jackson S, Baptist EW, Byers J, et al. The complex CD44 transcriptional unit: alternative splicing of three internal exons generates the epithelial form of CD44. Biochem Biophys Res Commun 1992; 182:569-78.
6. Screaton GR, Bell MV, Jackson DG, Gornelis RB, Gerth U, Bell JI. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992;89:12160-4.
7. Cooper DL, Dougherty GJ. To metastasize or not? Selection of CD44 splice sites. Nature Med 1995;1:635-7.
8. Gunthert U, Hofmann M, Rudy W, Reber S, Zoller M, Haussmann I, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991;65:13-24.
9. Rudy W, Hofmann M, Schwartz-Albiez R, Zoller M, Heider KH, Ponta H, et al. Two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: each one individually suffices to confer metastatic behavior. Cancer Res 1993;53:1262-8.
10. Koopman G, Heider KH, Horst E, Adolf GR, van den Berg F, Ponta H, et al. Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44. J Exp Med 1993; 177:897-904.
11. Heider KH, Hofman M, Hors E, van den Berg F, Ponta H, Herrlich P, et al. A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. J Cell Biol 1992;120:623-7.
12. Heider KH, Dammrich J, Angel SP, Hermelink MHK, Vollmers HP, Herrlich P, et al. Differential expression of CD44 splice variants in intestinal and diffuse-type human gastric carcinomas and normal gastric mucosa. Cancer Res 1993;53:4197-203.
13. Matsumura Y, Tarin D. Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 1992; 340:1053-8.
14. Namec RE, Toole BP, Knudson T. The cell surface hyaluronate binding sites of invasive human bladder carcinoma cells. Biochem Biophys Res Commun 1987;149:249-57.
15. Washimi O, Ueda R, Ariyoshi Y, Suyama M, Seki T, Takahashi T, et al. Expression of CD44 variant isoforms in normal and neoplastic cells of the lung. Jpn J Cancer Res 1994;85:1112-6.
16. Dali P, Heider KH, Hekele A, von Minckwitz G, Kaufmann M, Ponta H, et al. Surface expression and messenger RNA analysis of CD44 in uterine cervical cancer and normal cervical epithelium. Cancer Res 1994;54:3337-41.
17. Kuppner MC, Meir EV, Gauthier T, Hamou MF, De Tribolet N. Differential expression of the CD44 molecule in human brain tumors. Int J Cancer 1992;50:572-7.
18. Ross JS, del Rosario AD, Sanderson B, Bui HX. Selective expression of CD44 cell adhesion molecule in thyroid papillary carcinoma fine needle aspirates. Diagn Cytopathol 1996; 14:287-91.
19. Figge J, del Rosario AD, Gerasimov G, Dedov I, Bronstein M, Troshina K, et al. Preferential expression of the cell adhesion molecule CD44 in papillary thyroid carcinoma. Exp Mol Pathol 1995;61:203-11.
20. del Rosario AD, Bui HX, Wu AS, Kim DN, Figge H, Fisher HAG, et al. CD44 and E-cadherin expression in transitional cell carcinoma of the urinary bladder. Mod Pathol 1994; 7:73A.
21. Hong RL, Pu YS, Chu JS, Lee WJ, Chen YC, Wu CW. Correlation of expression CD44 isoforms and E-cadherin with differentiation in human urothelial cell lines and transitional cell carcinoma. Cancer Lett 1995;89:81-7.
22. Southgate J, Trejdosiewicz LK, Smith B, Selby PJ. Patterns of splice variant CD44 expression by normal human urothelium insitu and invitro and by bladder-carcinoma cell lines. Int J Cancer 1995;62:449-56.
23. Fujita N, Yaegashi N, Ide Y, Sato S, Nakamura M, Ishiwata I, et al. Expression of CD44 in normal human versus tumor endometrial tissues: possible implication of reduced expression of CD44 in lymph-vascular involvement of cancer cells. Cancer Res 1994;54:3922-8.
24. Salmi M, Virta GP, Sointu P, Grenman R, Kalimo H, Jalkanen S. Regulated expression of exon v6 containing isoforms of CD44 in man: downregulation during malignant transformation of tumors of squamocellular origin. J Cell Biol 1993;122:431-42.
25. Cannistra SA, Abu-Jawdeh G, Niloff J, Strobel T, Swanson L, Andersen J, et al. CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors. J Clin Oncol 1995;13:1912-21.
26. Shtivelman E, Bishop JM. Expression of CD44 is repressed in neuroblastoma cells. Mol Cell Biol 1991;11:5446-53.
27. Lokeshwar BL, Lokeshwar VB, Block NL. Expression of CD44 in prostate cancer cells: association with cell proliferation and invasive potential. Anticancer Res 1995;15:1191-8.
28. Welsh CF, Zhu D, Bourguignon LYW. Interaction of CD44 variant isoforms with hyaluronic acid and the cytoskeleton in human prostate cancer cells. J Cell Physiol 1995;164:605-12.
29. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992;23:273-9.
30. Telen MJ, Eisenbarth GS, Haynes BF. Human erythrocyte antigens: regulation of expression of a novel erythrocyte surface antigen by the inhibitor Lutheran [N(Lu)] gene. J Clin Invest 1983;71:1878-86.
31. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991; 39:741-8.
32. Ross JS, Nazeer T, Church K, Amato C, Figge H, Rifkin MD, et al. Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis. Cancer 1993;72:3020-8.
33. Mehta CR, Patel NR. Network algorithm for performing Fisher's exact test in R X C contingency tables. J Am Stat 1983; 78:427-39.
34. Jalkanen S, Joensuu H, Soderstrom KO, Klemi PJ. Lymphocyte homing and clinical behavior of non-Hodgkin's lymphoma. J Clin Invest 1991;87:1835-40.
35. Joensuu H, Klemi PJ, Toikkanen S, Jalkanen S. Glycoprotein CD44 expression and its association with survival in breast cancer. Am J Pathol 1993;143:867-74.
36. Washington MK, Gottfried MR, Telen MJ. Expression of the cell adhesion molecule CD44 in gastric adenocarcinoma. Lab Invest 1993;68:52A.
37. Harn HJ, Ho LI, Chang JY, Wu CW, Jiang SY, Lee HS, et al. Differential expression of the human metastases adhesion molecule CD44vin normal and carcinomatous stomach mucosa of Chinese subjects. Cancer 1995;75:1065-71.
38. Yokozaki H, Ito R, Nakayama H, Kuniyasu H, Taniyama K, Tahara E. Expression of CD44 abnormal transcripts in human gastric carcinomas. Cancer Lett 1994;83:229-34.
39. Dali P, Heider KH, Sinn HP, Angel PS, Adolf G, Kaufmann M, et al. Comparison of immunohistochemistry and RT-PCR for detection of CD44v-expression, a new prognostic factor in human breast cancer. Int J Cancer 1995;60:471-7.
40. Kaufmann M, Heider KH, Sinn HP, von Minckwitz G, Ponta H, Herrlich P. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 1995;345:615-9.
41. Tanabe KK, Ellis LM, Saya H. Expression of CD44R1 adhesion molecule in colon carcinomas and metastasis. Lancet 1993;341:725-6.
42. Mulder JWR, Kruyt PM, Sewnath M, Oosting J, Seldenrijkc A, Weidema WF, et al. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 1994;344:1470-2.
43. Takeuchi K, Yamaguchi A, Urano T, Goi T, Nakagawara G, Shiku H. Expression of CD44 variant exons 8-10 in colorectal cancer and its relationship to metastasis. Jpn J Cancer Res 1995;86:292-7.
44. Kainz CH, Kohlberger P, Sliutz G, Tempfer C, Heinzl H, Reinthaller A, et al. Splice variants of CD44 in human cervical cancer stage IB to IIB. Gynecol Oncol 1995;57:383-7.
45. Liu AY. Expression of CD44 in prostate cancer cells. Cancer Lett 1994;76:63-9.
46. Cannistra SA, Cansas GS, Niloff J, DeFranzo B, Kim Y, Ottensmeier C. Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Res 1993;53:3830-8.
47. Gross N, Beretta C, Peruisseau G, Jackson D, Simmons D, Beck D. CD44H expression by human neuroblastoma cells: relation to MYCN amplification and lineage differentiation. Cancer Res 1994;54:4238-42.
48. Mackay CR, Terpe HJ, Stauder R, Marston WL, Stark H, Gunthert U. Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 1994;124:71-82.
49. Ross JS, Figge HL, Bui HX, del Rosario AD, Fisher HAG, Nazeer T, Jennings TA, Ingle R, Kim DN. E cadherin expression in prostatic carcinoma biopsies: correlation with tumor grade, DNA content, pathologic stage and clinical outcome. Mod Pathol 1994;7:835-41.
50. Bussemakers MJ, van Moorselaar RJ, Giroldi LA, Ichikawa T, Isaacs JT, Takeichi M, Debruyne FMJ, Schalken JA. Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res 1992;52:2916-22.
51. Giroldi LA, Schalken JA. Decreased expression of the intercellular adhesion molecule E-cadherin in prostate cancer: biological significance and clinical implications. Cancer Metastasis Rev 1993;12:29-37.
52. Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HFM, Schaafsma HE, Debruine FMJ, Isaacs WB. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992; 52:5104-109.
53. Fox SB, Fawcett J, Jackson DG, Collins I, Gatter KC, Harris AL, et al. Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res 1994;54:4539-46.